{"id":390745,"date":"2017-12-29T00:00:00","date_gmt":"2017-12-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0009-2017-biopharma-breast-cancer-current-treatment-physician-insights-us-2017\/"},"modified":"2026-04-18T11:40:01","modified_gmt":"2026-04-18T11:40:01","slug":"cutron0009-2017-biopharma-breast-cancer-current-treatment-physician-insights-us-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0009-2017-biopharma-breast-cancer-current-treatment-physician-insights-us-2017\/","title":{"rendered":"Breast Cancer | Current Treatment: Physician Insights | US | 2017"},"content":{"rendered":"<p>The treatment of breast cancer requires a multidisciplinary approach incorporating surgery, radiotherapy, hormonal agents, targeted therapies, and chemotherapy. Treatment decisions are influenced by disease stage, resectability, and HER2 and HR status. Targeted treatment options for the HR-positive, HER2-negative segment have expanded in the United States following the market entries of Pfizer\u2019s Ibrance (2015) and Novartis\u2019s Kisqali (2017). This study shines a spotlight on the current treatment dynamics for HR-positive, HER2-negative breast cancer and examines how the triple-negative breast cancer population is now managed.<br \/>\n<strong>Questions answered:<\/strong><\/p>\n<ul>\n<li>What are the key drivers and obstacles determining current prescribing patterns for Ibrance in HR-positive\/HER2-negative metastatic breast cancer?<\/li>\n<li>What is the uptake of recently approved Kisqali in newly diagnosed HR-positive\/HER2-negative metastatic breast cancer? What is surveyed oncologists\u2019 perception of Kisqali versus Ibrance?<\/li>\n<li>In the absence of any approved targeted therapy for triple-negative breast cancer, what is the patient share of key chemotherapeutic agents and regimens prescribed to newly diagnosed patients?<\/li>\n<li>What is the most-frequently prescribed sequence of treatment for HR-positive\/HER2-negative metastatic breast cancer?<\/li>\n<\/ul>\n<p><strong>Key drugs covered:<\/strong><\/p>\n<ul>\n<li>Kisqali<\/li>\n<li>Ibrance<\/li>\n<li>Afinitor<\/li>\n<li>Abraxane<\/li>\n<li>Faslodex<\/li>\n<\/ul>\n<p><strong>Companies mentioned:<\/strong><\/p>\n<ul>\n<li>Pfizer<\/li>\n<li>Novartis<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390745","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-breast-cancer","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390745","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390745\/revisions"}],"predecessor-version":[{"id":393869,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390745\/revisions\/393869"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390745"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}